Determination of mesalazine, a low bioavailability OLSALAZINE (cas 15722-48-2) metabolite in human plasma by UHPLC–MS/MS: Application to a pharmacokinetic study
-
Add time:09/24/2019 Source:sciencedirect.com
OLSALAZINE (cas 15722-48-2) sodium, salicylate derivative (prodrug) is effectively bioconverted to mesalazine (5-aminosalicylic acid; 5-ASA), which has an anti-inflammatory activity in ulcerative colitis. In this article, a novel highly sensitive and selective method was developed and validated to determine mesalazine in human plasma using a derivatization technique to enhance the signal intensity by using ultra- high performance liquid chromatography coupled to tandem mass spectrometry (UHPLC–MS/MS) with an electrospray ionization interface. The sample preparation consisted of a derivatization with propionyl anhydride followed by liquid liquid extraction (LLE) to remove the interference and minimize the matrix effect of human plasma. The multiple reaction monitoring (MRM) mode of the negative ion was performed and the transitions of m/z 208.1 → 107.0 and m/z 211.1 → 110.1 were used to measure the derivative of mesalazine and mesalazine-d3. The chromatographic separation was achieved using kinetex XB-C18 (100 × 4.6 mm 2.6 μ) analytical column with 0.1% formic acid in water and acetonitrile as mobile phase with a gradient elution. Nominal retention times of mesalazine and IS were 3.08 and 3.07 min, respectively. Absolute recovery was found to be between 82–95% for analyte and about 78% for IS. The standard curves was linear (r2 > 0.995) in the concentration range 0.10 to 12.0 ng/mL with lower limit of quantification (LLOQ) in human plasma was 0.10 ng/mL. The average intra-day/inter-day precision values (%CV) were in the range from 0.6–2.9 % and 1.3–3.8 %, respectively, while the average accuracy value was 103.8–107.2%. This method has been successfully applied to the human pharmacokinetics of olsalazine sodium 250 mg capsules following single oral administration.
We also recommend Trading Suppliers and Manufacturers of OLSALAZINE (cas 15722-48-2). Pls Click Website Link as below: cas 15722-48-2 suppliers
Prev:An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “OLSALAZINE (cas 15722-48-2)”
Next:The risk premium of gold☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “OLSALAZINE (cas 15722-48-2)”09/10/2019
- Two three-dimensional pillared metal–OLSALAZINE (cas 15722-48-2) complexes based on infinite rod-shaped secondary building units09/09/2019
- Degradation kinetics of metronidazole and OLSALAZINE (cas 15722-48-2) by bacteria in ascending colon and in feces of healthy adults09/08/2019
- Full paperOld drug, new indication: OLSALAZINE (cas 15722-48-2) sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity09/07/2019
- Research paperEx vivo evaluation of degradation rates of metronidazole and OLSALAZINE (cas 15722-48-2) in distal ileum and in cecum: The impact of prandial state09/06/2019
- On the encapsulation of OLSALAZINE (cas 15722-48-2) by β-cyclodextrin: A DFT-based computational and spectroscopic investigations09/05/2019
- Synthesis of novel (bio) degradable linear azo polymers conjugated with OLSALAZINE (cas 15722-48-2)09/04/2019
- Enzyme and PH responsive 5-flurouracil (5-FU) loaded hydrogels based on OLSALAZINE (cas 15722-48-2) derivatives for colon-specific drug delivery09/03/2019


